| Pharmaceutical Information |
| Drug Name |
Nafarelin acetate |
| Drug ID |
BADD_D01514 |
| Description |
Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis. |
| Indications and Usage |
For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis. |
| Marketing Status |
Prescription |
| ATC Code |
H01CA02 |
| DrugBank ID |
DB00666
|
| KEGG ID |
D00990
|
| MeSH ID |
D017274
|
| PubChem ID |
25079036
|
| TTD Drug ID |
D08WYM
|
| NDC Product Code |
12869-731; 0025-0166 |
| Synonyms |
Nafarelin | Synarel | RS-94991-298 | RS 94991 298 | RS94991298 | Nafarelin Acetate | Nafarelin Acetate, Hydrate | Nafarelin Monoacetate |
|
| Chemical Information |
| Molecular Formula |
C68H87N17O15 |
| CAS Registry Number |
76932-60-0 |
| SMILES |
CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C
2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=C
N7)NC(=O)C8CCC(=O)N8.CC(=O)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
